TY - JOUR
T1 - Outcome of patients supported with the HeartMate 3 after extracorporeal life support
T2 - On behalf of the Durable Mechanical Circulatory Support After Extracorporeal Life Support Study Group
AU - Saeed, Diyar
AU - Stark, Christoffer
AU - Otto, Wolfgang
AU - Loforte, Antonio
AU - Zimpfer, Daniel
AU - Bernhardt, Alexander M.
AU - Potapov, Evgenij
AU - Morshius, Michiel
AU - Schibilsky, David
AU - Albert, Alexander
AU - Raweh, Ayman
AU - Riebandt, Julia
AU - Pappalardo, Federico
AU - Attisani, Matteo
AU - Rinaldi, Mauro
AU - Haneya, Assad
AU - Huenges, Katharina
AU - Ramjankhan, Faiz
AU - Jorde, Ulrich P.
AU - Lewin, Daniel
AU - Jawad, Khalil
AU - Aubin, Hug
AU - Ayala, Rafael
AU - Reichenspurner, Hermann
AU - Lichtenberg, Artur
AU - Borger, Michael
AU - Gummert, Jan
N1 - Publisher Copyright:
© 2023 The American Association for Thoracic Surgery
PY - 2023
Y1 - 2023
N2 - Objectives: The Durable Mechanical Circulatory Support System After Extracorporeal Life Support registry is a multicenter registry of patients who were bridged from extracorporeal life support to a durable mechanical circulatory support system. Although numerous studies have highlighted the favorable outcomes after implantation of the HeartMate 3 (Abbott), the objective of our study is to examine the outcomes of patients who received HeartMate 3 support after extracorporeal life support. Methods: Data of patients undergoing HeartMate 3 implantation from January 2016 to April 2022 at 14 centers were collected and evaluated. Inclusion criteria were patients with extracorporeal life support before HeartMate 3 implantation. The outcome was reported and compared with patients receiving other types of pumps. Results: A total of 337 patients were bridged to durable mechanical circulatory support system after extracorporeal life support in the study period. Of those patients, 140 were supported with the HeartMate 3. The other types of pumps included 170 HeartWare HVADs (Medtronic) (86%), 14 HeartMate II devices (7%), and 13 (7%) other pumps (7%). Major postoperative complications included right heart failure requiring temporary right ventricular assist device in 60 patients (47%). Significantly lower postoperative stroke (16% vs 28%, P = .01) and pump thrombosis (3% vs 8%, P = .02) rates were observed in the patients receiving the HeartMate 3. The 30-day, 1-year, and 3-year survivals in patients receiving the HeartMate 3 were 87%, 73%, and 65%, respectively. Conclusions: In this critically ill patient population, the survivals of patients who were transitioned to the HeartMate 3 are deemed acceptable and superior to those observed when extracorporeal life support was bridged to other types of durable mechanical circulatory support systems.
AB - Objectives: The Durable Mechanical Circulatory Support System After Extracorporeal Life Support registry is a multicenter registry of patients who were bridged from extracorporeal life support to a durable mechanical circulatory support system. Although numerous studies have highlighted the favorable outcomes after implantation of the HeartMate 3 (Abbott), the objective of our study is to examine the outcomes of patients who received HeartMate 3 support after extracorporeal life support. Methods: Data of patients undergoing HeartMate 3 implantation from January 2016 to April 2022 at 14 centers were collected and evaluated. Inclusion criteria were patients with extracorporeal life support before HeartMate 3 implantation. The outcome was reported and compared with patients receiving other types of pumps. Results: A total of 337 patients were bridged to durable mechanical circulatory support system after extracorporeal life support in the study period. Of those patients, 140 were supported with the HeartMate 3. The other types of pumps included 170 HeartWare HVADs (Medtronic) (86%), 14 HeartMate II devices (7%), and 13 (7%) other pumps (7%). Major postoperative complications included right heart failure requiring temporary right ventricular assist device in 60 patients (47%). Significantly lower postoperative stroke (16% vs 28%, P = .01) and pump thrombosis (3% vs 8%, P = .02) rates were observed in the patients receiving the HeartMate 3. The 30-day, 1-year, and 3-year survivals in patients receiving the HeartMate 3 were 87%, 73%, and 65%, respectively. Conclusions: In this critically ill patient population, the survivals of patients who were transitioned to the HeartMate 3 are deemed acceptable and superior to those observed when extracorporeal life support was bridged to other types of durable mechanical circulatory support systems.
KW - ECLS
KW - ECMO
KW - HeartMate 3
KW - MCS
KW - outcome
UR - http://www.scopus.com/inward/record.url?scp=85173982153&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85173982153&partnerID=8YFLogxK
U2 - 10.1016/j.jtcvs.2023.08.048
DO - 10.1016/j.jtcvs.2023.08.048
M3 - Article
C2 - 37689237
AN - SCOPUS:85173982153
SN - 0022-5223
JO - Journal of Thoracic and Cardiovascular Surgery
JF - Journal of Thoracic and Cardiovascular Surgery
ER -